Histological and functional characteristics of peritoneal membrane in peritoneal sclerosis of PD patients.
BACKGROUND
Function and structure of peritoneal membrane (PM) are impaired on peritoneal dialysis (PD). Peritoneal sclerosis is a common finding in peritoneal biopsies (PB) of PD patients. The aim of this study was to examine the impact of peritoneal sclerosis on peritoneal function and clinical parameters in PD patients submitted to peritoneal biopsy.


METHODS
A PB was performed on 31 PD patients during catheter removal due to malfunction or after drop-out from treatment. For each patient PM transport was evaluated by the last peritoneal equilibration test before PB. Each daily glucose load was calculated. Tissue was formalin-embedded and stained for histological and immunohistochemical studies.


RESULTS
Patients with submesothelial sclerosis and those with impairment of submesothelial basement membrane and subendothelial vascular membrane were submitted to a larger daily glucose load. Peritoneal sclerosis > 50 microns was more frequent in high transporters, who were exposed to larger daily glucose load compared to medium-high transporters. Mesothelial loss is correlated to peritoneal sclerosis and vascular injuries.


CONCLUSIONS
Peritoneal sclerosis is not constant in PD patients: it is related to the loss of mesothelium integrity, to the daily glucose load of PD treatment and to vascular injuries, but apparently not to the presence of inflammatory infiltrate. It remains a matter of debate how much the peritoneal sclerosis modifies the function of PM and how new more biocompatible PD solutions could reduce PM injury.
Bertoli
S V
SV
Nephrology and Dialysis Unit, Policlinico MultiMedica, 20099 Sesto San Giovanni, Milan, Italy. silvio.bertoli@multimedica.it
Buzzi
L
L
Ciurlino
D
D
Maccario
M
M
Traversi
L
L
Martino
S
S
Procaccio
M
M
D000199:Actins / Q000276:immunology; D000906:Antibodies / Q000032:analysis; D001706:Biopsy; D015314:Dialysis Solutions / Q000737:chemistry; D004848:Epithelium / Q000378:metabolism / Q000473:pathology*; D005337:Fibrin / Q000378:metabolism; D005347:Fibroblasts / Q000378:metabolism; D005947:Glucose / Q000008:administration & dosage / Q000032:analysis; D006801:Humans; D017737:Macrophages, Peritoneal / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000473:pathology; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010537:Peritoneum / Q000098:blood supply / Q000378:metabolism / Q000473:pathology*; D012598:Sclerosis
D000199:Actins; D000906:Antibodies; D015314:Dialysis Solutions; D005337:Fibrin; D005947:Glucose